MAC shows up on exams the way it shows up in real life: when a patient’s cell-mediated immunity is down, this “opportunist” takes the chance. If you can quickly recognize the classic settings (advanced HIV, chronic lung disease), the key lab clue (acid-fast bacilli with negative TB testing), and the treatment pattern (macrolide-based multidrug therapy), you’ll pick up a lot of easy Step points.
Where MAC Fits in Micro (and Why It’s “Atypical”)
Mycobacteria are aerobic, slow-growing organisms with mycolic-acid–rich cell walls, making them acid-fast on Ziehl–Neelsen/Kinyoun staining. The “big name” is Mycobacterium tuberculosis (MTB). MAC refers mainly to:
- Mycobacterium avium
- Mycobacterium intracellulare
They’re often grouped as “atypical” (nontuberculous) mycobacteria (NTM) because they:
- Are not MTB (and generally not transmitted person-to-person like TB)
- Frequently come from environmental reservoirs (water, soil)
- Cause disease mainly in immunocompromised patients or those with structural lung disease
First Aid cross-reference: Microbiology → Mycobacteria (MAC/atypical mycobacteria); HIV opportunistic infections (MAC prophylaxis/treatment).
Micro & Pathophysiology: What Makes MAC Tick
Key microbiology features
- Acid-fast bacilli (AFB) due to mycolic acids
- Slow-growing, may require specialized culture conditions
- Environmental exposure (e.g., water aerosols, soil)
Pathophysiology (Step-relevant)
MAC is a facultative intracellular pathogen that can survive in macrophages, especially when cell-mediated immunity (Th1 → IFN-γ → macrophage activation) is impaired.
- In advanced HIV, low CD4 counts mean:
- Decreased macrophage activation
- Poor granuloma formation
- Higher risk of dissemination
Clinical Presentations You Must Recognize
1) Disseminated MAC in advanced HIV/AIDS (classic Step scenario)
Who?
- Typically CD4 < 50 cells/mm³
Symptoms
- Fever
- Night sweats
- Weight loss
- Fatigue
- Diarrhea/abdominal pain (GI involvement can happen)
- Generalized lymphadenopathy
- Hepatosplenomegaly
Labs
- Can see anemia and markedly elevated alkaline phosphatase (suggesting hepatic/reticuloendothelial involvement)
High-yield clue:
AFB-positive organism in an AIDS patient with systemic symptoms and CD4 < 50 → think disseminated MAC, especially if TB testing isn’t fitting the story.
2) Pulmonary MAC (Step 2–leaning but still fair game on Step 1)
Who?
- Patients with underlying lung disease (COPD, bronchiectasis)
- Or older, thin individuals with chronic cough (sometimes described in boards-style vignettes)
Symptoms
- Chronic cough, sputum
- Fatigue, malaise
- Weight loss
- Sometimes hemoptysis
Imaging
- Can mimic TB with upper-lobe disease/cavities, or show nodular/bronchiectatic patterns (exam questions may keep it simple: “TB-like but not TB”)
3) Cervical lymphadenitis (more common in kids)
- Unilateral cervical lymph node enlargement
- May be chronic, minimally tender
Diagnosis: How to Separate MAC from TB on Exams
Core concept: AFB-positive ≠ TB
Both MTB and MAC can be acid-fast. You need the context + tests.
Step-style diagnostic approach
- AFB smear positive: tells you “mycobacteria likely,” not which one.
- Culture/PCR (NAAT): definitive speciation.
- TB skin test (PPD) / interferon-gamma release assay (IGRA):
- Often negative or not strongly positive in MAC (and can be falsely negative in advanced HIV anyway).
Practical exam clues
- AIDS + CD4 < 50 + disseminated systemic symptoms → MAC
- AIDS + CD4 < 200 + pneumonia + diffuse interstitial pattern → think Pneumocystis jirovecii (common distractor)
- Apex cavitary disease + risk factors + positive IGRA/PPD → MTB more likely
Treatment (and Why Monotherapy Is a Trap)
Disseminated MAC treatment (classic)
- Azithromycin or clarithromycin (macrolide backbone)
PLUS - Ethambutol
PLUS - Often rifabutin (especially in HIV) as a third agent
Why combination therapy?
To reduce resistance, particularly macrolide resistance (a big clinical problem and a testable principle).
HIV: Prophylaxis (very high yield)
- Primary prophylaxis for MAC when CD4 < 50:
- Azithromycin (commonly) or clarithromycin
First Aid cross-reference: HIV prophylaxis table (MAC prophylaxis at CD4 < 50 with azithromycin).
Duration (testable principle)
- Treat until:
- Immune reconstitution on ART (CD4 recovery), and
- Sustained clinical improvement
Exam questions may simply ask which regimen or when to start prophylaxis.
High-Yield Associations & Classic USMLE Clues
“Buzzwords” table
| Clue in the Stem | Think | Why it matters |
|---|---|---|
| HIV patient with CD4 < 50, fever, weight loss, night sweats | Disseminated MAC | Most classic MAC presentation on Step |
| AFB-positive but story doesn’t fit TB; exposure to water/soil | Nontuberculous mycobacteria | MAC is environmental and opportunistic |
| Need prophylaxis in HIV at very low CD4 | Azithromycin | Commonly tested threshold: < 50 |
| Treatment uses macrolide + ethambutol ± rifabutin | MAC regimen | Recognize multi-drug approach |
| “TB-like” pulmonary disease in someone with chronic lung disease | Pulmonary MAC | Can mimic TB but management differs |
MAC vs MTB: Don’t Get Tricked
| Feature | MAC | MTB |
|---|---|---|
| Reservoir | Environment (water/soil) | Humans (classically) |
| Transmission | Not typically person-to-person | Airborne droplets |
| Key risk group | CD4 < 50, structural lung disease | Crowding, immunosuppression, endemic exposure |
| Typical disease | Disseminated in AIDS; chronic lung disease | Pulmonary TB; extrapulmonary TB |
| Therapy | Macrolide + ethambutol ± rifabutin | RIPE (rifampin, isoniazid, pyrazinamide, ethambutol) |
Rapid Review: What to Memorize Tonight
- MAC = Mycobacterium avium-intracellulare, acid-fast, opportunistic, environmental.
- Disseminated MAC: AIDS with CD4 < 50, systemic symptoms (fever, night sweats, weight loss), ± diarrhea, lymphadenopathy, hepatosplenomegaly.
- Prophylaxis when CD4 < 50: azithromycin.
- Treatment: azithro/clarithro + ethambutol ± rifabutin (avoid monotherapy).